Medpace Holdings Inc Hits 20-Day Low Amid Market Weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 04 Dec 25
Source: Coinmarketcap
Medpace Holdings Inc experienced a price decline of 4.06%, hitting a 20-day low amid broader market conditions.
The Nasdaq-100 is down 0.21%, indicating a slight weakness in the tech sector, while the S&P 500 remains relatively stable with minimal change. This overall market sentiment has contributed to Medpace's downward movement.
Investors may be cautious as the market shows signs of weakness, which could impact future performance. Medpace's position in the market may require close monitoring as broader economic factors continue to evolve.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MEDP is 569.17 USD with a low forecast of 462.00 USD and a high forecast of 660.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 597.910
Low
462.00
Averages
569.17
High
660.00
Current: 597.910
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
